TRCT
RXRX icon

Tower Research Capital (TRC)’s Recursion Pharmaceuticals RXRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.7K Sell
25,254
-14,608
-37% -$48.6K ﹤0.01% 2244
2026
Q1 		$122K Buy
39,862
+34,293
+616% +$133K ﹤0.01% 2032
2025
Q4 		$22.8K Sell
5,569
-156,102
-97% -$773K ﹤0.01% 2999
2025
Q3 		$789K Buy
161,671
+84,501
+109% +$444K 0.02% 613
2025
Q2 		$390K Sell
77,170
-23,835
-24% -$117K 0.01% 1188
2025
Q1 		$534K Buy
101,005
+95,578
+1,761% +$697K 0.02% 799
2024
Q4 		$36.7K Buy
5,427
+616
+13% +$4.14K ﹤0.01% 2755
2024
Q3 		$31.7K Sell
4,811
-29,252
-86% -$210K ﹤0.01% 2972
2024
Q2 		$255K Buy
34,063
+19,585
+135% +$171K ﹤0.01% 1887
2024
Q1 		$144K Buy
14,478
+874
+6% +$9.73K ﹤0.01% 1621
2023
Q4 		$134K Buy
13,604
+5,314
+64% +$37.9K ﹤0.01% 2411
2023
Q3 		$63.4K Sell
8,290
-10,228
-55% -$102K ﹤0.01% 2351
2023
Q2 		$138K Buy
18,518
+3,574
+24% +$25K ﹤0.01% 1817
2023
Q1 		$100K Buy
14,944
+12,645
+550% +$100K ﹤0.01% 1874
2022
Q4 		$18K Sell
2,299
-13,112
-85% -$129K ﹤0.01% 3232
2022
Q3 		$164K Buy
15,411
+10,649
+224% +$108K ﹤0.01% 2117
2022
Q2 		$39K Buy
4,762
+1,824
+62% +$12.2K ﹤0.01% 3127
2022
Q1 		$21K Sell
2,938
-1,171
-28% -$12.4K ﹤0.01% 3494
2021
Q4 		$70K Buy
4,109
+3,528
+607% +$66.4K ﹤0.01% 2491
2021
Q3 		$14K Sell
581
-1,931
-77% -$54.7K ﹤0.01% 4040
2021
Q2 		$91K Buy
+2,512
New +$74.3K ﹤0.01% 2506

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s RXRX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Recursion Pharmaceuticals (RXRX) stake by 37% in Q2 2026, selling an estimated $48.6K and leaving 25,254 shares worth $92.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2244.

Tower Research Capital (TRC) first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $789K in Q3 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Tower Research Capital (TRC) held 25,254 shares of Recursion Pharmaceuticals worth $92.7K as of Q2 2026.
  • Tower Research Capital (TRC) sold 14,608 Recursion Pharmaceuticals shares in Q2 2026, an estimated $48.6K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2244 holding.
  • Tower Research Capital (TRC) first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s Recursion Pharmaceuticals position peaked at $789K in Q3 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.